FORT MYERS, FL / ACCESSWIRE / October 28, 2022 / NeoGenomics, Inc. (NASDAQ:NEO) (the "Company"), a leading provider of cancer-focused genetics testing services and global oncology contract research ...
Late last week, MolDX informed the Company that additional clinical evidence is needed in order to secure Medicare coverage for RaDaRTM for Colorectal Cancer (CRC). Specifically, MolDX asked for a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback